Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis.

Regenerative Therapy
Jalil Tavakol-AfshariAli Gorji

Abstract

Stem cell-based treatments have emerged as potentially effective approaches to delay the progression of amyotrophic lateral sclerosis (ALS). This study was designed as a single-center, prospective, and open-label study without a placebo control group to assess the safety and efficacy of concurrent intrathecal (IT) and intravenous (IV) administration of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with ALS. Autologous BM-MSCs were isolated and expanded under standard conditions. Fifteen patients were neurologically examined before BM-MSCs transplantation (1 × 10 6 cells/kg BW) to evaluate the rate of pre-treatment disease progression. To assess the safety and efficacy, patients were examined at 1, 3, and 6 months following the treatment with BM-MSCs. Adverse reactions were assessed, and the clinical outcome was determined by the evaluation of the ALS functional rating scale-revised (ALSFRS-R) and forced vital capacity (FVC). No serious adverse reaction was observed after combined IT and IV administration of BM-MSCs. The mean ALSFRS-R and FVC values remained stable during the first 3 months of the treatment. However, a significant reduction in ALSFRS-R and FVC levels was observed in these patients 6...Continue Reading

References

Jul 24, 2001·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·B R BrooksUNKNOWN World Federation of Neurology Research Group on Motor Neuron Diseases
Jul 1, 2006·Neurological Research·Letizia MazziniFranca Fagioli
Nov 30, 2006·Neurology·A CzaplinskiS H Appel
Dec 21, 2006·Cell Transplantation·Rishi D S Nandoe TewarieMartin Oudega
Jun 22, 2007·Journal of the Neurological Sciences·Letizia MazziniFranca Fagioli
Mar 11, 2008·Trends in Neurosciences·Masatoshi Suzuki, Clive N Svendsen
Dec 12, 2012·Molecular Pharmaceutics·Vaibhav MundraRam I Mahato
Aug 27, 2014·Stem Cell Research & Therapy·Christina M Lewis, Masatoshi Suzuki
Sep 4, 2015·Current Stem Cell Research & Therapy·Mahsa HajivaliliMehdi Yousefi
Sep 12, 2017·Current Osteoporosis Reports·Haniyeh HemmatianG Harry van Lenthe
Oct 5, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Ammar Al-ChalabiLeonard H van den Berg
Jul 27, 2018·Annals of Neurology·Ki-Wook OhSeung Hyun Kim
Apr 9, 2020·Frontiers in Neuroscience·Emilio Geijo-BarrientosSalvador Martínez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.